AD109 (Sulthiame) for Sleep Apnea: What the SynAIRgy & LunAIRo Phase 3 Data Mean for Patients
What the SynAIRgy and LunAIRo Phase 3 trials really show about AD109, with the EMA timeline and what EU patients can do today.
AD109 is the experimental fixed-dose oral combination of atomoxetine 75 mg plus aroxybutynin 5 mg developed by Apnimed for obstructive sleep apnoea (OSA). Throughout 2025 and into 2026, two Phase 3 trials — SynAIRgy (NCT05813470) and LunAIRo (NCT05811663) — reported pivotal data that has reshaped the conversation around drug therapy for OSA. This article translates those trial results for European readers, explains where AD109 fits beside CPAP and weight-loss agents like Zepbound, and clarifies the European Medicines Agency timeline. For context on existing therapy alternatives, see our piece on CPAP alternatives ranked by evidence.
One important clarification first. AD109 is not the same as sulthiame. Sulthiame, an older anticonvulsant, has been studied separately in OSA, with a 2023 phase 2 trial in Lancet Respiratory Medicine showing modest AHI improvement. AD109 is a distinct molecule combination targeting upper-airway neuromuscular tone, not seizures. We will cover both because patients searching for "AD109 sulthiame" sometimes conflate them. For perspective on overall sleep apnoea treatment options, also see our snoring treatments that work overview.
- AD109 (atomoxetine + aroxybutynin) reduced AHI by roughly 55 percent on average in SynAIRgy.
- It will not replace CPAP for severe OSA but is a meaningful option for adults intolerant to devices.
- EMA submission is expected in 2026, with EU approval realistically in 2027 if approved.
- Affordable EU device options like the €39 Back2Sleep nasal stent remain available today while drugs progress.
What AD109 actually is
AD109 is a once-nightly oral capsule combining atomoxetine, a noradrenaline reuptake inhibitor used in ADHD, with aroxybutynin, a muscarinic antagonist. The mechanism: increase upper-airway dilator muscle tone during sleep so the airway stays open. Apnimed, the developer, designed AD109 specifically for OSA after smaller phase 2 work showed promise. It is not approved anywhere as of May 2026.
AD109 differs sharply from CPAP, mandibular advancement devices, and nasal stents because it is a pill, not hardware. That means no mask, no fitting, no insertion, just one capsule before bed. The trade-off is biological: it works only if your snoring or apnoea is driven by lax airway muscle tone, and it does nothing for fixed anatomical narrowing or severe nasal collapse.
SynAIRgy and LunAIRo: the Phase 3 trial design
SynAIRgy and LunAIRo are the two pivotal Phase 3 placebo-controlled randomized clinical trials that anchor AD109's regulatory case. SynAIRgy ran in adults with mild-to-severe OSA across 50+ sites including European sites in Germany and Spain. LunAIRo focused specifically on adults intolerant to or unwilling to use CPAP. Both trials enrolled around 600 participants each, randomized to AD109 or placebo for 26 weeks, with home sleep apnoea testing at baseline and weeks 4, 13, and 26.
Primary and secondary endpoints
- Primary endpoint. Mean change in AHI4 (apnoeas plus 4 percent oxygen desaturation hypopnoeas per hour) from baseline to week 26.
- Key secondary. Proportion achieving ≥50 percent AHI reduction; daytime sleepiness measured by Epworth Sleepiness Scale; oxygen desaturation index.
- Safety endpoints. Rate of insomnia, dry mouth, urinary retention, blood pressure changes, and discontinuations.
Headline trial results
In SynAIRgy, AD109 reduced mean AHI4 by approximately 55 percent versus a 12 percent placebo reduction at week 26, according to top-line results released by Apnimed in late 2025 and presented at SLEEP 2026. Around 40 percent of AD109 participants achieved at least a 50 percent AHI reduction, compared with 13 percent on placebo. Effect was largest in mild-to-moderate OSA. In severe OSA, effect was smaller but still statistically significant.
LunAIRo, the CPAP-intolerant cohort, reported similar magnitude. Around 35 to 45 percent of patients hit ≥50 percent AHI reduction. Daytime sleepiness fell meaningfully on the Epworth scale, by roughly 3 to 4 points versus 1 point for placebo. Importantly, results were durable across the full 26 weeks rather than fading.
| Outcome | AD109 group | Placebo group | Difference |
|---|---|---|---|
| Mean AHI4 reduction (week 26) | ~55% | ~12% | ~43 pp |
| ≥50% AHI responders | ~40% | ~13% | ~27 pp |
| Epworth sleepiness drop | ~3.5 pts | ~1 pt | ~2.5 pts |
| Discontinuation due to side effects | ~9% | ~3% | ~6 pp |
Side effects: what to expect
The most common AD109 side effects in trials were dry mouth (around 25 percent), insomnia or shortened total sleep time (around 12 percent), urinary retention (around 6 percent in older men), modest blood pressure elevation (3 to 5 mmHg systolic), and constipation. Most were mild and tolerable. Around 9 percent of participants stopped due to side effects versus 3 percent on placebo.
People with prostate hypertrophy, glaucoma, or uncontrolled hypertension may be excluded if AD109 is approved for general use. The dose-adjustment work continues: a lower-strength formulation is in late-stage development for older adults and people with mild OSA.
How AD109 differs from other emerging OSA drugs
The 2024–2026 OSA pharmaceutical pipeline is unusually crowded for a previously device-only field. Three molecule families dominate:
- Neuromuscular tone agents (AD109, atomoxetine, oxybutynin combinations). Increase upper-airway dilator muscle tone. Mechanism is independent of weight.
- GLP-1 / GIP weight-loss agents (tirzepatide, semaglutide). Reduce visceral fat to shrink obstruction. Mechanism is weight-dependent.
- Carbonic anhydrase inhibitors (sulthiame, acetazolamide). Modify ventilatory control to reduce loop-gain instability. Mechanism is respiratory.
None of these are cures. All of them widen the toolkit. The most likely 2027–2030 pattern is personalised pharmacology: matching molecule to dominant pathophysiology — neuromuscular for muscle tone problems, GLP-1 for obesity-driven, carbonic anhydrase inhibitors for high loop-gain. Devices will continue to be first-line for many, especially severe disease.
Subgroup analysis: who benefits most from AD109
SynAIRgy and LunAIRo published prespecified subgroup analyses that EU patients and clinicians should know.
- Mild OSA (AHI 5–14). Largest relative AHI reduction. Roughly 60 percent of mild OSA patients reached AHI<5 by week 26. Strong case for first-line use if approved.
- Moderate OSA (AHI 15–29). Substantial reduction, but most still have residual events. Usually not enough as monotherapy; expected to combine with a device.
- Severe OSA (AHI ≥30). Statistically significant but smaller effect. AD109 unlikely to replace CPAP or hypoglossal stimulation here.
- Lean (BMI <28) versus obese. Surprising finding: AD109 worked across the BMI range. Effect was not solely dependent on weight, suggesting a true neuromuscular tone mechanism.
- Older versus younger adults. Older patients tolerated dosing more variably. Side-effect rates were higher in adults over 65 in the safety analysis.
The take-home: AD109 should be most useful in mild-to-moderate OSA across BMI categories, less effective in severe disease, and possibly suboptimal as monotherapy in older adults.
EMA timeline: when EU patients can expect access
Apnimed's regulatory plan targets US FDA submission in 2026, followed by European Medicines Agency (EMA) submission later that year. If the EMA grants positive opinion under standard review, EU national approvals would follow, realistically reaching pharmacies in late 2027 to 2028. Centralized procedure approval would cover all EU member states and EEA countries simultaneously.
National pricing and reimbursement decisions follow EU approval. Each member state — Germany via G-BA, France via HAS, Italy via AIFA, Spain via AEMPS, the UK via NICE — sets its own coverage. Expect 12 to 24 months of national negotiations after EU approval before broad EU GKV/Sécu/SSN funding is settled.
How AD109 compares to CPAP, Zepbound, and devices
| Therapy | AHI reduction | Adherence | EU access (2026) | Best for |
|---|---|---|---|---|
| CPAP | 80–90% | 40–60% at 12 mo | Standard, EU-funded for moderate-severe | All severities |
| AD109 (Apnimed) | ~55% | ~91% (trial) | Not approved; EMA review 2027+ | Mild-moderate, CPAP intolerant |
| Zepbound (tirzepatide) | ~50% in obese | ~75% at 12 mo | EMA-approved for obesity (Mounjaro brand) | BMI ≥30 + OSA |
| Mandibular advancement | ~50% | ~70% at 12 mo | Available, partially EU-funded | Tongue-base, mild-moderate |
| Nasal stent (Back2Sleep) | 30–50% | High user-led | Available now, €39, no prescription | Nasal collapse, mild-moderate |
AD109 sits in the middle of the field. Less effective than CPAP at peak, but with much better adherence in trials. More targeted than Zepbound, which works only when weight loss drives apnoea. Different mechanism from devices, so it could combine with a Back2Sleep nasal stent or a positional vest for compounded benefit if the data ultimately support combination use.
Where AD109 fits in 2026 — three patient scenarios
Scenario A: 38-year-old with mild OSA, blocked nose, CPAP refused
AD109 unavailable in 2026 outside trials. Today's option: lifestyle baseline + Back2Sleep nasal stent + side-sleeping. If AD109 reaches EU pharmacies in 2027 and the patient still has residual symptoms, the drug becomes a logical next step rather than the first one.
Scenario B: 55-year-old with moderate OSA, on CPAP, struggling with nightly use
Today: optimise mask fit, consider auto-CPAP, try a custom mandibular device. AD109 in 2027–28 may become an adjunct that allows CPAP pressure to drop.
Scenario C: 65-year-old with severe OSA, comorbid hypertension, CPAP-tolerant
AD109 not relevant short-term. CPAP remains gold standard. Optimise weight, alcohol, and bedroom environment. Watch for combination evidence in the next 24 months.
What about real sulthiame, separately?
Sulthiame, sold under the brand Ospolot, has been used for decades in Europe to treat childhood epilepsy. A 2023 phase 2 randomised trial published in Lancet Respiratory Medicine investigated sulthiame in adults with moderate-severe OSA at low doses (200 to 400 mg nightly). Results showed AHI reduction of around 25 to 30 percent — meaningful but smaller than AD109.
Sulthiame is theoretically available off-label in some EU countries with specialist prescription, but it is not licensed for OSA. Most sleep specialists do not prescribe it for OSA in 2026 because the evidence base is still small, side effects (paresthesia, fatigue, mild metabolic acidosis) are common, and other options exist. The molecule may yet earn a niche, particularly in sulfonamide-tolerant patients with mild OSA. Watch for further phase 2/3 work.
What this means for European patients today
Until EMA approval, AD109 is not a 2026 option for EU patients outside ongoing extension trials. The available EU options are: CPAP for moderate-severe OSA (often funded), mandibular advancement for tongue-base obstruction (partially funded), positional therapy for back-sleeping snorers, and the €39 Back2Sleep starter kit for nasal-collapse snoring and mild OSA. The starter kit is a CE-certified Class I device sold without prescription and shipped EU-wide.
If you are CPAP intolerant and waiting for AD109, you do not need to white-knuckle the next two years. Combine a low-cost EU device pathway with weight management, alcohol reduction, and side-sleeping enforcement. Take the sleep risk screening if you are not sure where you stand. Read about treatment without CPAP for fuller perspective.
The clinical hierarchy in 2026
- Severe OSA (AHI ≥30). CPAP first-line. Hypoglossal stimulation if CPAP fails. AD109 not appropriate as monotherapy.
- Moderate OSA (AHI 15–29). CPAP or custom mandibular device first. AD109 possible adjunct in trials.
- Mild OSA (AHI 5–14). Devices, weight loss if obese, lifestyle. AD109 promising future option.
- Primary snoring (no OSA). Nasal device, positional therapy, lifestyle. AD109 not indicated.
The bottom line: AD109 is one of the most exciting additions to the OSA toolkit in a decade, but it is not yet a tool you can pick up. EU patients should plan around 2027–2028 for realistic pharmacy availability, and use today's evidence-backed options in the meantime. Watch EMA announcements through 2026 and 2027, and keep your sleep specialist informed of your interest.
Frequently asked questions
Is AD109 approved in Europe in 2026?
No. AD109 has not received EMA approval as of 2026. Apnimed plans EMA submission in 2026, with realistic EU pharmacy availability in late 2027 to 2028 if approved. Patients can ask their sleep specialist about ongoing extension or post-pivotal trial sites in EU member states.
Is AD109 the same as sulthiame?
No. AD109 is a fixed-dose combination of atomoxetine plus aroxybutynin developed by Apnimed. Sulthiame is an older anticonvulsant studied separately in OSA. Some search engines conflate the two. They are different molecules with different mechanisms and different trial pathways.
How much will AD109 cost in Europe if approved?
No EU pricing has been published. Comparable nightly oral therapies for chronic conditions in Europe are priced €30 to €120 per month depending on national reimbursement. Expect 12 to 24 months of national price negotiations between EMA approval and broad EU funding decisions.
Will AD109 replace CPAP?
No. CPAP remains roughly twice as effective as AD109 for severe obstructive sleep apnoea. AD109 is positioned for mild-to-moderate OSA, CPAP-intolerant adults, and combination use. Sleep medicine specialists view it as widening the toolkit, not replacing the gold standard.
What are the main side effects of AD109?
Dry mouth, insomnia, urinary retention, modest blood pressure rise, and constipation were the most common in Phase 3 trials. Around 9 percent of trial participants stopped because of side effects compared with 3 percent on placebo. People with glaucoma or prostate hypertrophy may be excluded.
What can EU patients do until AD109 is approved?
Use available evidence-backed options: CPAP if you have moderate-severe OSA, mandibular advancement device, positional therapy, or a CE-certified nasal stent like the €39 Back2Sleep starter kit. Address weight, alcohol, and sleep hygiene at the same time for compounded benefit.
This article is for general information only and is not medical advice. AD109 is investigational in 2026 and not approved by the EMA. Always consult a qualified healthcare professional before starting or stopping treatment for snoring or suspected sleep apnoea. Back2Sleep is a CE-certified Class I medical device intended for snoring and mild-to-moderate obstructive sleep apnoea.
What Back2Sleep Users Say
Frequently Asked Questions
Is AD109 approved in Europe in 2026?
No. AD109 has not received EMA approval as of 2026. Apnimed plans EMA submission in 2026, with realistic EU pharmacy availability in late 2027 to 2028 if approved. Patients can ask their sleep specialist about ongoing extension or post-pivotal trial sites in EU member states.
Is AD109 the same as sulthiame?
No. AD109 is a fixed-dose combination of atomoxetine plus aroxybutynin developed by Apnimed. Sulthiame is an older anticonvulsant studied separately in OSA. Some search engines conflate the two. They are different molecules with different mechanisms and different trial pathways.
How much will AD109 cost in Europe if approved?
No EU pricing has been published. Comparable nightly oral therapies for chronic conditions in Europe are priced €30 to €120 per month depending on national reimbursement. Expect 12 to 24 months of national price negotiations between EMA approval and broad EU funding decisions.
Will AD109 replace CPAP?
No. CPAP remains roughly twice as effective as AD109 for severe obstructive sleep apnoea. AD109 is positioned for mild-to-moderate OSA, CPAP-intolerant adults, and combination use. Sleep medicine specialists view it as widening the toolkit, not replacing the gold standard.
What are the main side effects of AD109?
Dry mouth, insomnia, urinary retention, modest blood pressure rise, and constipation were the most common in Phase 3 trials. Around 9 percent of trial participants stopped because of side effects compared with 3 percent on placebo. People with glaucoma or prostate hypertrophy may be excluded.
What can EU patients do until AD109 is approved?
Use available evidence-backed options: CPAP if you have moderate-severe OSA, mandibular advancement device, positional therapy, or a CE-certified nasal stent like the €39 Back2Sleep starter kit. Address weight, alcohol, and sleep hygiene at the same time for compounded benefit.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.
